A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

June 15, 2026

Study Completion Date

June 15, 2026

Conditions
Neuroblastoma
Interventions
DIETARY_SUPPLEMENT

β-glucan

"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."

DRUG

GM-CSF

"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."

BIOLOGICAL

OPT-821

Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER